Rare ashy dermatosis-like hyperpigmentation associated with osimertinib.

Thorac Cancer

First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Published: May 2022

AI Article Synopsis

  • Osimertinib is a first-line treatment for non-small cell lung cancer with EGFR mutations, recognized for its effectiveness as a tyrosine kinase inhibitor.
  • Instances of skin-related side effects, like hyperpigmentation, are uncommon with this drug, and documented cases are rare.
  • In this report, a patient developed ashy dermatosis-like hyperpigmentation from osimertinib, but despite dose reduction, treatment continued due to the ongoing benefits observed in their condition.

Article Abstract

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is the most reliable EGFR-TKI and is widely used as the first-line treatment for EGFR mutation-positive non-small cell lung cancer. Pigmentary changes caused by EGFR-TKIs are unusual, and to the best of my knowledge, hyperpigmentation with osimertinib has rarely been reported as a skin-related adverse event. Here, I report a case of osimertinib-associated ashy dermatosis-like hyperpigmentation on imaging. Although reducing the dose of osimertinib to 40 mg did not improve pigmentation, osimertinib use was continued due to its clinical and radiological benefit, which persisted for a long time.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058305PMC
http://dx.doi.org/10.1111/1759-7714.14383DOI Listing

Publication Analysis

Top Keywords

ashy dermatosis-like
8
dermatosis-like hyperpigmentation
8
osimertinib
5
rare ashy
4
hyperpigmentation associated
4
associated osimertinib
4
osimertinib osimertinib
4
osimertinib third-generation
4
third-generation epidermal
4
epidermal growth
4

Similar Publications

Article Synopsis
  • - Pigmentary disorders like Lichen planus pigmentosus (LPP) and vitiligo can lead to significant cosmetic concerns and psychosocial stress for patients.
  • - A 61-year-old man with LPP developed vitiligo and was successfully treated with low-dose isotretinoin and topical tacrolimus ointment.
  • - The coexistence of LPP and vitiligo might be explained by an autoimmune process affecting skin pigmentation called melanocytorrhagy.
View Article and Find Full Text PDF
Article Synopsis
  • Osimertinib is a first-line treatment for non-small cell lung cancer with EGFR mutations, recognized for its effectiveness as a tyrosine kinase inhibitor.
  • Instances of skin-related side effects, like hyperpigmentation, are uncommon with this drug, and documented cases are rare.
  • In this report, a patient developed ashy dermatosis-like hyperpigmentation from osimertinib, but despite dose reduction, treatment continued due to the ongoing benefits observed in their condition.
View Article and Find Full Text PDF

Ribociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor that has been approved in combination with endocrine therapy for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative advanced or metastatic breast cancer. The main dermatological adverse events associated with CDK 4/6 inhibitors that are described in the literature include skin rash, an increased risk of alopecia, and stomatitis. Erythema dyschromicum perstans (EDP), also known as ashy dermatosis, is characterized by acquired small and large slate-gray hyperpigmented macules with erythematous borders.

View Article and Find Full Text PDF

Osimertinib-associated ashy dermatosis-like hyperpigmentation.

JAAD Case Rep

February 2020

Division of Dermatology, Department of Internal Medicine, Faculty of Medicine, Skin and Allergy Research Unit, Chulalongkorn University, Bangkok, Thailand.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!